Bionano Genomics Announces Canadian College of Medical Geneticists Presentation Featuring Applications of OGM for Genetic Research
June 03 2022 - 08:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome
mapping (OGM) solutions on the Saphyr® system and provider of
NxClinical™ software, the leading solution for visualization,
interpretation and reporting of genomic data, today announced that
researchers from University Health Network in Toronto, Columbia
University Medical Center, and Children’s Hospital of Eastern
Ontario will deliver a two-hour presentation on technologies and
applications of OGM for genetic research at the Canadian
College of Medical Geneticists (CCMG) General Meeting 2022. The
CCMG conference will be held virtually this year and runs from June
6-10, 2022.
Details of the presentation:
Category: Workshop 2 Session Time: Wednesday, June 8,
2022 – 11:35A-1:35A (PST)Title: New Technologies and
Applications of Optical Genome MappingPresenters: Dr. Brynn
Levy, Professor of Pathology and Cell Biology at Columbia
University Medical Center, Dr. Adam Smith, Director of the Cancer
Cytogenetics Laboratory at University Health Network, and Dr. Lijia
Huang, Clinical Molecular Geneticist at Children’s Hospital of
Eastern Ontario
For more details and to register for the conference, please
visit
https://hopin.com/events/ccmg-46th-annual-scientific-meeting/registration.
“We are pleased that researchers at University Health Network,
Children’s Hospital of Eastern Ontario, and Columbia University
Medical Center will be presenting at the CCMG conference on the
pioneering research they are doing with OGM. Our customers continue
to push forward cutting-edge applications in areas including
prenatal testing and cancer diagnosis and we look forward to the
authors sharing their research with the CCMG community. We
thank Dr. Smith, Dr. Levy, and Dr. Huang for their commitment
to OGM and we are impressed by their innovative drive,” commented
Erik Holmlin, PhD, president and chief executive officer
of Bionano Genomics.
About Bionano GenomicsBionano Genomics is a
provider of genome analysis solutions that can enable researchers
and clinicians to reveal answers to challenging questions in
biology and medicine. The Company’s mission is to transform the way
the world sees the genome through OGM solutions, diagnostic
services and software. The Company offers OGM solutions for
applications across basic, translational and clinical research.
Through its Lineagen business, the Company also provides diagnostic
testing for patients with clinical presentations consistent with
autism spectrum disorder and other neurodevelopmental disabilities.
Through its BioDiscovery business, the Company also offers an
industry-leading, platform-agnostic software solution, which
integrates next-generation sequencing and microarray data designed
to provide analysis, visualization, interpretation and reporting of
copy number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view. For more
information, visit www.bionanogenomics.com,
www.lineagen.com or www.biodiscovery.com
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Mar 2023 to Mar 2024